Want to join the conversation?
$ABBV updated its EPS guidance to include impact of Stemcentrx acquisition, which is expected to be $0.20 dilutive in 2016. As result, $ABBV now sees adjusted EPS of $4.62-4.82 for 2016, representing 10% growth versus 2015 at the midpoint. $ABBV's EPS guidance is $3.87-4.07 on a GAAP basis.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.